Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENOXAMED vs LOVENOX in Acute Coronary Syndromes
NCT02152423Phase 1Completed
- Sponsor
- Université de Monastir
- Start
- Jun 2013
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of enoxaparin in acute coronary syndrome (ACS) (2 arms), sponsored by Université de Monastir. Primary endpoint: Anti-Xa Activity at 4 hours. Started Jun 2013; status: completed.
02
Drugs
enoxaparin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02152423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152423.